What is Leerink Partnrs' Estimate for SPRY FY2027 Earnings?

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) - Stock analysts at Leerink Partnrs reduced their FY2027 earnings per share estimates for shares of ARS Pharmaceuticals in a report issued on Wednesday, November 13th. Leerink Partnrs analyst R. Ruiz now anticipates that the company will post earnings per share of $0.55 for the year, down from their prior estimate of $0.60. The consensus estimate for ARS Pharmaceuticals' current full-year earnings is ($0.64) per share.

A number of other research firms have also recently commented on SPRY. Leerink Partners upped their price target on shares of ARS Pharmaceuticals from $21.00 to $25.00 and gave the stock an "outperform" rating in a report on Friday, September 20th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $30.00 target price on shares of ARS Pharmaceuticals in a research report on Tuesday, October 8th. Raymond James upgraded ARS Pharmaceuticals from an "outperform" rating to a "strong-buy" rating and boosted their price target for the company from $18.00 to $22.00 in a report on Tuesday, August 13th. Finally, William Blair upgraded ARS Pharmaceuticals to a "strong-buy" rating in a report on Friday, August 30th. Four equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, ARS Pharmaceuticals currently has a consensus rating of "Buy" and an average price target of $24.00.

ARS Pharmaceuticals Stock Performance

SPRY stock traded down $0.10 during midday trading on Friday, reaching $14.01. The company's stock had a trading volume of 1,533,755 shares, compared to its average volume of 811,041. ARS Pharmaceuticals has a 1 year low of $4.28 and a 1 year high of $18.51. The firm has a market capitalization of $1.36 billion, a price-to-earnings ratio of -27.67 and a beta of 0.90. The stock has a fifty day simple moving average of $14.58 and a two-hundred day simple moving average of $11.67.

Institutional Trading of ARS Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the business. SG Americas Securities LLC purchased a new position in shares of ARS Pharmaceuticals in the 1st quarter valued at approximately $119,000. Russell Investments Group Ltd. acquired a new stake in shares of ARS Pharmaceuticals during the first quarter worth $60,000. Vanguard Group Inc. lifted its stake in shares of ARS Pharmaceuticals by 37.0% during the first quarter. Vanguard Group Inc. now owns 2,886,455 shares of the company's stock worth $29,500,000 after buying an additional 779,969 shares during the period. Public Employees Retirement System of Ohio purchased a new stake in shares of ARS Pharmaceuticals during the first quarter valued at $172,000. Finally, Paloma Partners Management Co acquired a new position in shares of ARS Pharmaceuticals in the 1st quarter valued at $103,000. Hedge funds and other institutional investors own 68.16% of the company's stock.

Insider Transactions at ARS Pharmaceuticals

In other ARS Pharmaceuticals news, COO Brian Dorsey sold 50,000 shares of the stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $15.00, for a total transaction of $750,000.00. Following the completion of the sale, the chief operating officer now directly owns 6,024 shares of the company's stock, valued at approximately $90,360. This represents a 89.25 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Eric Karas sold 10,000 shares of ARS Pharmaceuticals stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $14.00, for a total transaction of $140,000.00. Following the completion of the transaction, the insider now directly owns 5,693 shares in the company, valued at approximately $79,702. The trade was a 63.72 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,584,351 shares of company stock valued at $24,152,378. Company insiders own 40.10% of the company's stock.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.